Sector News

Merck cans both its COVID-19 vaccines due to weak clinical data

January 31, 2021
Life sciences

Merck has stopped development of its two COVID-19 vaccine candidates after getting a look at phase 1 data. The vaccine powerhouse said neither candidate triggered immune responses comparable to those achieved by rival jabs, leading Merck to cut its losses and focus on COVID-19 therapeutics.

Last year, Merck executives emphasized the proven nature of their vaccine platforms and cast doubts on the likelihood of rivals with more experimental technologies completing development in months. The narrative was that, while companies such as Moderna and Pfizer had taken early leads by using mRNA, Merck would come from behind and deliver the effective, scalable, one-dose vaccines needed to end the pandemic.

Things played out differently in reality. Moderna and Pfizer, working with BioNTech, smashed Merck’s record for the fastest vaccine R&D program and delivered stellar data that left little room for rivals to improve on short-term efficacy. Now, Merck has exited the COVID-19 vaccine race altogether.

Merck dropped out of the race after reviewing phase 1 data on V590 and V591. A full post mortem will take place when Merck publishes the results in a peer-reviewed journal, but the top-line findings explain the decision. The immune responses to V590 and V591 were inferior to the natural responses seen in patients infected with SARS-CoV-2 and the responses triggered by rival vaccines. Cross-trial immune comparisons can be unreliable, but clearly the data were weak enough to kill the vaccines.

The decision marks the end for V590 and V591. Merck worked on recombinant vesicular stomatitis virus vaccine V590 with IAVI, building on its experience of busing the vector to protect against Ebola. V591 is a measles virus vector vaccine Merck acquired in its takeover of Themis.

Merck has achieved success with other replicating virus vaccines. However, the travails of V590 and V591 could kill off the approach in COVID-19. Other companies, notably AstraZeneca and Johnson & Johnson, are working on non-replicating viral vector vaccines but Merck was the most prominent developer of replicating viral vaccines.

The failures of V590 and V591 end Merck’s status as a prominent developer of COVID-19 vaccines, although the Big Pharma is yet to completely step away from the space. IAVI said it is continuing to work with Merck to evaluate whether changing the route of administration will improve outcomes.

For now, Merck’s COVID-19 efforts are focused on two therapeutics that are nearing key readouts. Full results from a phase 3 trial of MK-7110, the fusion protein Merck acquired in its takeover of OncoImmune, are scheduled for the first quarter of 2021. Initial efficacy data from a phase 2/3 trial of the Ridgeback Bio-partnered molnupiravir are due around the same time. Merck said it will share the initial efficacy data publicly if the results are clinically meaningful.

by Nick Paul Taylor

Source: fiercebiotech.com

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend